ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Xyosted Prefilled Autoinjector for Subcutaneous Testosterone Administration
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 156035" data-attributes="member: 13851"><p>Here is one of the first studies (pilot study) done at Royal Victoria Hospital, Montreal, Quebec, Canada, using the sub-q method with an insulin syringe.</p><p></p><p>The paper is from 2006.....study was done in 2002.</p><p></p><p>My urologist who manages my trt started a trial treating his patients using the sub-q method injected into abdominal fat shortly after it came out and has been doing so ever since.</p><p></p><p>In Canada, he is considered one of the pioneers regarding using sub-q injections for treating men on trt.</p><p></p><p></p><p></p><p></p><p><strong><span style="color: rgb(184, 49, 47)">Subcutaneous administration of testosterone </span></strong></p><p>A pilot study report</p><p></p><p></p><p><strong>Objective</strong></p><p></p><p><em>To investigate the effect of low doses of subcutaneous testosterone in hypogonadal men since the intramuscular route, which is the most widely used form of testosterone replacement therapy, is inconvenient to many patients.</em></p><p></p><p></p><p><strong>Methods</strong></p><p></p><p><em>All men with primary and secondary hypogonadism attending the reproductive endocrine clinic at Royal Victoria Hospital, Montreal, Quebec, Canada, were invited to participate in the study. </em><span style="color: rgb(184, 49, 47)"><em><strong>Subjects were enrolled from January 2002 till December 2002. Patients were asked to self-administer weekly low doses of testosterone enanthate using a 0.5 ml insulin syringe. </strong></em></span></p><p></p><p></p><p><strong>Results</strong></p><p></p><p><em>A total of 22 patients were enrolled in the study. ABSTRACT The mean trough was 14.48 ± 3.14 nmol/L and peak total testosterone was 21.65 ± 7.32 nmol/L. For the free testosterone, the average trough was 59.94±20.60 pmol/L and the peak was 85.17 ± 32.88 pmol/L. All of the patients delivered testosterone with ease and no local reactions were reported.</em></p><p></p><p></p><p><strong>Conclusion</strong></p><p></p><p><span style="color: rgb(184, 49, 47)"><strong><em>Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels.</em></strong></span><em><strong> <span style="color: rgb(44, 130, 201)">T</span></strong></em><span style="color: rgb(44, 130, 201)"><strong><em>his is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route. </em></strong></span></p><p></p><p></p><p></p><p></p><p>At the end of the paper, it is stated:</p><p></p><p></p><p><em><strong>"In conclusion, this is the first report on the use of subcutaneous testosterone administration, which with new syringe technology appeared to be a safe, inexpensive, and effective form of treatment for hypogonadal men. Although the number of patients using subcutaneous testosterone was small, the overall clinical response was satisfactory. A large-scale study is needed to confirm these results. </strong></em><strong><span style="color: rgb(26, 188, 156)"><em>We foresee the production of a testosterone “pen” delivery system in the future"</em></span></strong></p><p></p><p></p><p></p><p></p><p>Xyosted auto-injector FDA approved in 2019.....who knew?</p><p></p><p>LOL<img src="data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7" class="smilie smilie--sprite smilie--sprite8" alt=":D" title="Big Grin :D" loading="lazy" data-shortname=":D" /></p></blockquote><p></p>
[QUOTE="madman, post: 156035, member: 13851"] Here is one of the first studies (pilot study) done at Royal Victoria Hospital, Montreal, Quebec, Canada, using the sub-q method with an insulin syringe. The paper is from 2006.....study was done in 2002. My urologist who manages my trt started a trial treating his patients using the sub-q method injected into abdominal fat shortly after it came out and has been doing so ever since. In Canada, he is considered one of the pioneers regarding using sub-q injections for treating men on trt. [B][COLOR=rgb(184, 49, 47)]Subcutaneous administration of testosterone [/COLOR][/B] A pilot study report [B]Objective[/B] [I]To investigate the effect of low doses of subcutaneous testosterone in hypogonadal men since the intramuscular route, which is the most widely used form of testosterone replacement therapy, is inconvenient to many patients.[/I] [B]Methods[/B] [I]All men with primary and secondary hypogonadism attending the reproductive endocrine clinic at Royal Victoria Hospital, Montreal, Quebec, Canada, were invited to participate in the study. [/I][COLOR=rgb(184, 49, 47)][I][B]Subjects were enrolled from January 2002 till December 2002. Patients were asked to self-administer weekly low doses of testosterone enanthate using a 0.5 ml insulin syringe. [/B][/I][/COLOR] [B]Results[/B] [I]A total of 22 patients were enrolled in the study. ABSTRACT The mean trough was 14.48 ± 3.14 nmol/L and peak total testosterone was 21.65 ± 7.32 nmol/L. For the free testosterone, the average trough was 59.94±20.60 pmol/L and the peak was 85.17 ± 32.88 pmol/L. All of the patients delivered testosterone with ease and no local reactions were reported.[/I] [B]Conclusion[/B] [COLOR=rgb(184, 49, 47)][B][I]Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels.[/I][/B][/COLOR][I][B] [COLOR=rgb(44, 130, 201)]T[/COLOR][/B][/I][COLOR=rgb(44, 130, 201)][B][I]his is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route. [/I][/B][/COLOR] At the end of the paper, it is stated: [I][B]"In conclusion, this is the first report on the use of subcutaneous testosterone administration, which with new syringe technology appeared to be a safe, inexpensive, and effective form of treatment for hypogonadal men. Although the number of patients using subcutaneous testosterone was small, the overall clinical response was satisfactory. A large-scale study is needed to confirm these results. [/B][/I][B][COLOR=rgb(26, 188, 156)][I]We foresee the production of a testosterone “pen” delivery system in the future"[/I][/COLOR][/B] Xyosted auto-injector FDA approved in 2019.....who knew? LOL:D [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Xyosted Prefilled Autoinjector for Subcutaneous Testosterone Administration
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top